Ku Yee-Huang, Chuang Yin-Ching, Yu Wen-Liang
Division of Infectious Disease, Department of Internal Medicine, Chi Mei Medical Center, Liouying, Taiwan.
J Microbiol Immunol Infect. 2008 Aug;41(4):332-6.
Strains of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae have spread widely in Taiwan hospitals. In this study, we evaluated the in vitro antimicrobial activity of tigecycline against ESBL-producing Enterobacteriaceae, including Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae.
104 confirmed ESBL-producing bacteria were isolated from 4 hospitals in mid- and southern Taiwan between 2000 and 2006. The in vitro activity of tigecycline against these ESBL producers was tested by use of Etest strips.
The minimal tigecycline concentration at which 50% of isolates were inhibited and minimal concentration at which 90% of isolates were inhibited for ESBL-producing isolates ranged from 0.38 to 0.75 microg/mL and 0.5 to 1.5 microg/mL, respectively.
Tigecycline, a new semisynthetic glycylcycline, may be considered an alternative drug of choice for patients infected with ESBL-producing bacteria.
产超广谱β-内酰胺酶（ESBL）的肠杆菌科细菌菌株已在台湾医院广泛传播。在本研究中，我们评估了替加环素对产ESBL的肠杆菌科细菌的体外抗菌活性，这些细菌包括肺炎克雷伯菌、粘质沙雷菌和阴沟肠杆菌。
2000年至2006年间，从台湾中南部的4家医院分离出104株确诊产ESBL的细菌。使用Etest试纸条检测替加环素对这些产ESBL细菌的体外活性。
产ESBL分离株的替加环素最低抑菌浓度（50%菌株被抑制时的浓度）和最低杀菌浓度（90%菌株被抑制时的浓度）分别为0.38至0.75μg/mL和0.5至1.5μg/mL。
替加环素是一种新型半合成甘氨酰环素，可被视为感染产ESBL细菌患者的替代首选药物。
Zotero 插件